비만 치료 시장 : 치료 종류, 투여 경로, 환자 연령층, 성별, 비만 유형, 판매 채널, 최종사용자별 - 세계 예측(2026-2032년)

The Obesity Treatment Market is projected to grow by USD 61.38 billion at a CAGR of 15.64% by 2032.

Obesity Treatment Market Introduction

Obesity treatment has moved from episodic weight-loss management to evidence-based chronic disease care. The World Health Organization reports that more than 1 billion people were living with obesity in 2022, including 879 million adults and 159 million children and adolescents, making the condition one of the most significant global health burdens.

Demand is being driven by rising cardiometabolic disease, broader clinical acceptance of anti-obesity medications, expanding bariatric and endoscopic options, and payer interest in reducing obesity-linked costs from type 2 diabetes, cardiovascular disease, sleep apnea, osteoarthritis, and certain cancers. Clinical guidelines increasingly position obesity management as long-term care that combines lifestyle intervention, pharmacotherapy, surgical evaluation, behavioral support, and continuous monitoring.

Transformative Shifts in Obesity Care

The obesity treatment landscape is undergoing a structural shift as GLP-1 receptor agonists and dual incretin therapies redefine clinical expectations for durable weight reduction. Landmark trial results, including cardiovascular risk reduction evidence for semaglutide in selected patients with obesity and established cardiovascular disease, have elevated obesity treatment from cosmetic weight loss to risk-based medical intervention.

At the same time, care delivery is becoming multidisciplinary. Nutrition therapy, behavioral health, remote monitoring, pharmacotherapy, bariatric surgery, and maintenance programs are increasingly integrated to improve adherence, minimize weight regain, and support long-term metabolic outcomes. Regulatory agencies and clinical societies are also emphasizing safety surveillance, patient selection, and continuity of care as demand for evidence-backed obesity treatment accelerates.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating obesity treatment by improving patient identification, risk stratification, treatment matching, and adherence support. AI-enabled analytics can mine electronic health records to identify patients with obesity-related complications who may benefit from pharmacotherapy, intensive lifestyle intervention, or bariatric evaluation.

The cumulative impact is strongest where AI supports clinical workflow rather than replacing clinician judgment. Predictive models, connected scales, digital coaching, and automated prior authorization tools can reduce friction in care pathways, while safeguards for bias, privacy, interoperability, and clinical validation remain essential. AI can also support real-world evidence generation by tracking persistence, adverse events, weight trajectories, and cardiometabolic outcomes across diverse patient populations.

Key Regional Insights

North America remains a high-value obesity treatment region due to elevated disease prevalence, strong specialist networks, and fast uptake of novel anti-obesity medications. CDC data show U.S. adult obesity prevalence at 40.3% for August 2021 to August 2023, sustaining demand for medical, surgical, behavioral, and digital interventions, while Canada continues to advance obesity as a chronic disease within guideline-led care. Europe is shaped by universal health systems, health technology assessment, and cost-effectiveness scrutiny, with Germany, France, Italy, Spain, and the United Kingdom balancing prevention priorities with access to advanced pharmacotherapy and bariatric services.

Asia-Pacific is expanding as urbanization, dietary change, and sedentary lifestyles increase obesity and diabetes risk, especially across China, India, Australia, Japan, and South Korea. Latin America, led by Brazil and Mexico, faces high obesity and diabetes burdens but uneven reimbursement and fragmented access to specialist care. The Middle East, particularly GCC markets, is prioritizing obesity because of high diabetes prevalence and national chronic disease strategies, while Africa is managing a dual burden of undernutrition and rising obesity in urban populations, increasing the need for scalable prevention, primary care screening, and affordable treatment pathways.

Key Group Insights

The G7 has the strongest concentration of advanced obesity treatment infrastructure, including clinical research capacity, reimbursement pathways, regulatory maturity, and specialist obesity care. The European Union supports harmonized drug regulation through the European Medicines Agency, while national health systems determine access and cost controls, making evidence generation, comparative effectiveness, and health-economic value critical for adoption.

BRICS countries combine very large patient pools with uneven access to specialist care, creating opportunities for scalable, lower-cost care models, local manufacturing, and primary care-led obesity management. ASEAN markets are influenced by rapid urbanization, nutrition transition, and growing diabetes prevalence, while GCC countries are investing in chronic disease management, digital health infrastructure, and premium healthcare services. NATO is not a health bloc, but its member countries increasingly view metabolic health as relevant to workforce readiness, healthcare system resilience, and long-term productivity.

Key Country Insights

The United States is the most commercially dynamic obesity treatment market because of high prevalence, strong drug adoption, employer interest, specialist capacity, and active debate on insurance coverage. Canada is advancing chronic disease-oriented obesity care through clinical guidelines and multidisciplinary services, while Mexico and Brazil face substantial obesity and diabetes burdens that support demand for accessible pharmacologic, surgical, nutritional, and lifestyle-based solutions.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are expanding obesity services under budget-sensitive public systems, with reimbursement tied to evidence, clinical prioritization, and health technology assessment. Russia presents a large population base with variable access to advanced therapies and specialist obesity management. China and India have enormous addressable populations and rising metabolic disease risk linked to urbanization and lifestyle change, while Japan, South Korea, and Australia show strong demand for clinically validated, guideline-aligned care models that integrate pharmacotherapy, digital support, and long-term monitoring.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based positioning that connects weight reduction with measurable metabolic, cardiovascular, functional, and quality-of-life outcomes. Commercial strategies should align with obesity as a chronic, relapsing disease requiring maintenance therapy, adherence support, individualized escalation, and long-term patient monitoring.

Organizations should expand partnerships with payers, employers, health systems, primary care networks, and digital health platforms to improve access and persistence. Investment in real-world evidence, safety monitoring, supply reliability, clinician education, culturally tailored care, and affordability will be critical as demand outpaces traditional obesity care capacity. Leaders should also prepare for stricter scrutiny around patient selection, long-term safety, discontinuation outcomes, and equitable access.

Research Methodology

This executive summary is developed through secondary research using publicly available, data-backed sources including WHO, CDC, national health agencies, regulatory bodies, peer-reviewed clinical trials, clinical guidelines, and official health system publications. Insights are triangulated across epidemiology, treatment adoption, regulatory activity, reimbursement trends, clinical outcomes, and regional healthcare infrastructure.

The methodology emphasizes verified facts, market-relevant interpretation, and cross-regional comparison. No unsupported market-sizing claims are used; conclusions are framed around documented disease burden, approved therapies, clinical evidence, real-world care dynamics, and observable healthcare system trends. Regional, group, and country insights are synthesized narratively to maintain clarity, and decision-useful context.

Conclusion

Obesity treatment is entering a new phase defined by chronic disease management, advanced pharmacotherapy, multidisciplinary care, and data-enabled patient engagement. The scale of global obesity, combined with clinical evidence linking treatment to broader health outcomes, is expanding the strategic importance of obesity care across healthcare systems.

Organizations that pair scientific credibility with access strategies, digital support, supply resilience, and long-term outcome measurement will be best positioned to capture growth while improving population health. Sustainable success will depend on demonstrating durable outcomes, supporting equitable access, and integrating obesity treatment into routine cardiometabolic care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Obesity Treatment Market, by Treatment Type

• 7.1. Pharmacological Treatments
  • 7.1.1. Appetite Suppressants
  • 7.1.2. Lipase Inhibitors
  • 7.1.3. GLP-1 Receptor Agonists
  • 7.1.4. Combination Therapies
• 7.2. Surgical Treatments
  • 7.2.1. Gastric Bypass
  • 7.2.2. Sleeve Gastrectomy
  • 7.2.3. Adjustable Gastric banding
  • 7.2.4. Biliopancreatic Diversion with Duodenal switch
• 7.3. Device-Based Treatments
  • 7.3.1. Intragastric Balloons
  • 7.3.2. Endoscopic Sleeve Gastroplasty
  • 7.3.3. Electrical Stimulation Systems

8. Obesity Treatment Market, by Route of Administration

• 8.1. Oral
• 8.2. Injectable
• 8.3. Transdermal

9. Obesity Treatment Market, by Patient Age Group

• 9.1. Adults
• 9.2. Elderly
• 9.3. Pediatric

10. Obesity Treatment Market, by Gender

• 10.1. Male
• 10.2. Female

11. Obesity Treatment Market, by Obesity Type

• 11.1. Class I (BMI 30-35)
• 11.2. Class II (BMI 35-40)
• 11.3. Class III (Severe/Morbid obesity, BMI >=40)

12. Obesity Treatment Market, by Distribution Channel

• 12.1. Offline
• 12.2. Online

13. Obesity Treatment Market, by End-User

• 13.1. Hospitals & Clinics
• 13.2. Specialty Clinics
• 13.3. Weight Loss & Wellness Centers

14. Obesity Treatment Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Obesity Treatment Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Obesity Treatment Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Novo Nordisk A/S
• 18.2. Eli Lilly and Company
• 18.3. WW International, Inc.
• 18.4. Amgen Inc.
• 18.5. Noom, Inc.
• 18.6. AstraZeneca PLC
• 18.7. Herbalife Ltd.
• 18.8. Hims & Hers Health, Inc.
• 18.9. Rhythm Pharmaceuticals, Inc.
• 18.10. Zealand Pharma A/S
• 18.11. Omada Health Inc.
• 18.12. Boston Scientific Corporation
• 18.13. IEH Biopharma LLC
• 18.14. Medifast, Inc.
• 18.15. Sanofi SA
• 18.16. Takeda Pharmaceutical Company Limited
• 18.17. Pfizer, Inc.
• 18.18. Viking Therapeutics, Inc.
• 18.19. Currax Pharmaceuticals LLC
• 18.20. ReShape Lifesciences, Inc.
• 18.21. AbbVie Inc.
• 18.22. Atkins Nutritionals, Inc.
• 18.23. BTL Aesthetics
• 18.24. C.H. Boehringer Sohn AG & Ko. KG
• 18.25. F. Hoffmann-La Roche Ltd
• 18.26. GlaxoSmithKline plc.
• 18.27. Johnson & Johnson Services, Inc.
• 18.28. Kellogg Company
• 18.29. Medtronic PLC
• 18.30. Merck & Co.
• 18.31. NutriSystem, Inc.
• 18.32. Olympus Corporation